Framework engineering to produce dominant T cell receptors with enhanced antigen-specific function.
Sharyn ThomasFiyaz MohammedRogier M ReijmersAnnemarie L WoolstonTheresa StaussAlan KennedyDavid R StirlingAngelika HollerLouisa GreenDavid T JonesKatherine K MatthewsDavid A PriceBenjamin M ChainMirjam H M HeemskerkEmma Catherine MorrisBenjamin E WillcoxHans J StaussPublished in: Nature communications (2019)
TCR-gene-transfer is an efficient strategy to produce therapeutic T cells of defined antigen specificity. However, there are substantial variations in the cell surface expression levels of human TCRs, which can impair the function of engineered T cells. Here we demonstrate that substitutions of 3 amino acid residues in the framework of the TCR variable domains consistently increase the expression of human TCRs on the surface of engineered T cells.The modified TCRs mediate enhanced T cell proliferation, cytokine production and cytotoxicity, while reducing the peptide concentration required for triggering effector function up to 3000-fold. Adoptive transfer experiments in mice show that modified TCRs control tumor growth more efficiently than wild-type TCRs. Our data indicate that simple variable domain modifications at a distance from the antigen-binding loops lead to increased TCR expression and improved effector function. This finding provides a generic platform to optimize the efficacy of TCR gene therapy in humans.
Keyphrases
- regulatory t cells
- poor prognosis
- endothelial cells
- gene therapy
- cell proliferation
- wild type
- cell surface
- binding protein
- amino acid
- induced pluripotent stem cells
- dendritic cells
- long non coding rna
- stem cells
- cell therapy
- adipose tissue
- high fat diet induced
- copy number
- machine learning
- metabolic syndrome
- genome wide
- dna methylation
- data analysis
- signaling pathway
- insulin resistance
- single cell
- transcription factor
- electron transfer